Skip to main content

Table 4 Immunohistochemistry assays for PD-L1 expression

From: Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Drug

Antibody (marker)

Rx line

Tumor type

Targeted cells

Tumor specimen

Cutoff point (%)

ORR % in IHC+ cases (95 % CI)

ORR % in IHC− cases (95 % CI)

Predictive role

P value

References

Nivolumab

28-8 rabbit (Dako)

1 L

Melanoma

TCs

Archival FFPE or new biopsy

5

58 (46,69)

41 (35,48)

Yes

0.001

Larkin J (2015) [130]

Nivolumab + ipilimumab

72 (60,82)

55 (48,62)

Yes

0.001

Nivolumab

≥2 L

5

44 (30,58)

20 (11,32)

Yes

NA

Weber JS (2015) [128]

Nivolumab + ipilimumab

1 L

5

58 (37,78)

55 (42,69)

No

>0.05

Postow MA (2015) [4]

Nivolumab

1 L

5

53 (41,64)

33 (25,42)

No

>0.05

Robert C (2015) [129]

≥2 L

NSCLC

TCs

Archival FFPE or new biopsy

1

31 (23,40)

9 (5,16)

Yes

0.002

Paz-Ares L (2015) [156]; Updated in Borghaei H (2015) [126]

5

36 (26,46)

10 (6,17)

Yes

0.002

10

37 (27,48)

11 (6,17)

Yes

0.002

≥2 L

Archival FFPE

1

17 (9,29)

17 (8,29)

No

0.9364

Brahmer JR (2015) [125]

5

21 (10,37)

15 (8,25)

No

0.2908

10

19 (8,36)

16 (9,26)

No

0.6411

≥2 L

Archival FFPE

1

20 (5,35)

13 (2,28)

No

>0.05

Rizvi NA (2015) [131]

5

24 (5,43)

14 (3,25)

No

1 L

Archival FFPE

5

31 (NA)

10 (NA)

No

>0.05

Gettinger SN (2015) [157]

Nivolumab + ipilimumab

1 L

Archival FFPE

5

19 (NA)

14 (NA)

No

>0.05

Antonia SJ (2014) [158]

Nivolumab

5H1 and anti-PD-1 monoclonal M3

≥2 L

Archival FFPE

5

39 (34,44)

6 (1,12)

Yes

0.025

Taube JM (2014) [113]

Pembrolizumab

22C3 mouse (Dako)

≥1 L

NSCLC

TCs and ICs

New biopsy

50

45 (33,57)

17 (10,25)

Yes

0.001

Garon EB (2015) [5]

1 L

New biopsy

50

47 (23,72)

19 (8,38)

Yes

NA

Rival NA (2015) [159]

Any

Archival FFPE

1

25 (NA)

13 (NA)

Yes

NA

Garon EB (2014) [160]

≥1 L

Archival FFPE

50

30 (23,39)

9.8 (NA)

Yes

NA

Herbst RS (2015) [140]

29 (22,37)

10.7 (NA)

1 L

Archival FFPE

50

16 (NA)

10 (NA)

Yes

NA

Garon EB (2014) [161]

Atezolizumab (MPDL3280A)

SP142 rabbit (Roche Ventana)

≥2 L

NSCLC

TCs and ICs

Archival FFPE and new biopsy

50

45 (23,68)

14 (6,25)

Yes

NA

Leora H (2015) [162]

≥2 L

NSCLC

1+

31 (25,37)

20 (14,26)

Yes

0.015

Herbst RS (2014) [145]

Solid Tumor

1+

29 (27,31)

13 (10,16)

Yes

0.007

≥2 L

NSCLC

2+

18 (NA)

8 (NA)

Yes

NA

Spira AI (2015) [143]

Durvalumab (MEDI-4736)

SP263 rabbit (Roche Ventana)

≥2 L

NSCLC

TCs

Archival FFPE and new biopsy

25

39 (NA)

5 (NA)

Yes

NA

Segal NH (2014) [163]

33 (13,59)

30 (16,47)

No for combo

NA

Antonia SJ (2016) [155];

22 (3, 60)

29 (8, 58)

No for monotherapy

NA

  1. NA not available